Managing HIV/hepatitis C co-infection in the era of direct acting antivirals

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Rockstroh, Jürgen K ^a   Bhagani, Sanjay ^b,c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Foundation Trust   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Direct acting antivirals; Hepatitis C; HIV; Interferon; Ribavirin

Indexed keywords

ABACAVIR; ABT 333; ANTIVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; DACLATASVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FALDAPREVIR; LAMIVUDINE; MARAVIROC; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PLACEBO; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TENOFOVIR;

ANEMIA; ANTIVIRAL THERAPY; DECREASED APPETITE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER FIBROSIS; MIXED INFECTION; NAUSEA; NEUTROPENIA; PRURITUS; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VOMITING;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; RIBAVIRIN;

EID: 84887914208     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-234     Document Type: Review

References (27)

1. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, Cavassini M, Calmy A, Bernasconi E, Schmid P, Flepp M, Kowalska J, Ledergerber B, Swiss HIV Cohort Study (SHCS) Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013, 14:195-207. 10.1111/j.1468-1293.2012.01051.x, 22998068, Swiss HIV Cohort Study (SHCS).
2. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J, EuroSIDA Study Group Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005, 192:992-1002. 10.1086/432762, 16107951, EuroSIDA Study Group.
3. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J, EuroSIDA Study Group Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008, 198:1337-1344. 10.1086/592171, 18767985, EuroSIDA Study Group.
4. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, Fischer HP, Oldenburg J, Brackmann HH, Sauerbruch T. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996, 91:2563-2568.
5. Lacombe K, Rockstroh J. HIV and viral hepatitis co-infections: advances and challenges. Gut 2012, 61:i47-i58. 10.1136/gutjnl-2012-302062, 22504919.
6. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus co-infection. Lancet 2003, 362:1708-1713. 10.1016/S0140-6736(03)14844-1, 14643119.
7. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450. 10.1056/NEJMoa040842, 15282351, APRICOT Study Group.
8. Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los Santos I, San Joaquín I, Echeverría S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, García-Samaniego J, Soriano V, PRESCO Study Group Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007, 23:972-982. 10.1089/aid.2007.0011, 17725413, PRESCO Study Group.
9. Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Serrão R, Sola R, Bertasso A, Passe And S, Stancic S. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012, 13:142-152. 10.1310/hct1303-142, 22592094.
10. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Combination therapy with telaprevir for chronic hepatitis C Virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013, 159:86-96.
11. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W, P05411 study investigators Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013, 13:597-605. 10.1016/S1473-3099(13)70149-X, 23768747, P05411 study investigators.
12. Cotte L, Braun J, Lascoux-Combe C, Vincent C, Pol S, Valentin M-A, Lacombe K, Nau D, Aboulker JP, Molina J-M, ANRS HC26 Study Group High early virological response with telaprevir-pegylated-interferon-ribavirin in treatment-experienced hepatitis C virus genotype 1/HIV co-infected patients: ANRS HC26 TelapreVIH Study. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta 2013, abstract 36, ANRS HC26 Study Group.
13. Poizot-Martin I, Bellissant E, Piroth L, Renault A, Quertainmont Y, Rosenthal E, Alric L, Guyader D, Bourliere M, Molina J-M, ANRS-HC27 BOCEPREVIH Study Group ANRS-HC27 BocepreVIH interim analysis: high early virologic response with boceprevir + pegylated interferon + ribivirin in hepatitis C Virus/HIV co-infected patients with previous failure to pegylated interferon + ribivirin. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta 2013, abstract 37, ANRS-HC27 BOCEPREVIH Study Group.
14. Vogel M, Rockstroh JK. The treatment of chronic hepatitis C virus infection in HIV co-infection. Eur J Med Res 2009, 14:507-515. 10.1186/2047-783X-14-12-507, 3351935, 20149983.
15. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren J, Rockstroh J, Kirk O, Mocroft A, EuroSIDA in EuroCoord Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med 2013, 14:614-623. EuroSIDA in EuroCoord.
16. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011, 9:509-516. 10.1016/j.cgh.2011.03.004, 21397729.
17. Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J, GESIDA3603/5607 Study Group Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009, 50:407-413. 10.1002/hep.23020, 19575364, GESIDA3603/5607 Study Group.
18. Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bellón JM, González-García J, GESIDA HIV/HCV Cohort Study Group Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012, 55:728-736. 10.1093/cid/cis500, 22610932, GESIDA HIV/HCV Cohort Study Group.
19. Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bellón JM, González-García J, GESIDA HIV/HCV Cohort Study Group Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol 2013, 58:1104-1112. 10.1016/j.jhep.2013.01.042, 23395690, GESIDA HIV/HCV Cohort Study Group.
20. Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 2013, 369:321-342. 10.1007/978-3-642-27340-7_13, 23463207.
21. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013, 59:434-441. 10.1016/j.jhep.2013.04.035, 23669289.
22. Dieterich D, Soriano V, Nelson M, Rockstroh J, Arasteh K, Bhagani S, Talal A, Tural C, Vinisko R, Kort J. STARTVerso 4: high rates of early virologic response in hepatitis C Virus genotype 1/HIV co-infected patients treated with faldaprevir + pegylated interferon and ribavirin. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta 2013, abstract 40LB.
23. Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology 2013, 57:2143-2154. 10.1002/hep.26276, 23359516.
24. Dieterich D, Rockstroh J, Orkin C, Gutierrez F, Klein M, Reynes J, Jessner W, Lenz O, Peeters M, Beumont-Mauviel M. Simeprevir with pegylated interferon/ribavirin in patients co-infected with chronic hepatitis C virus and HIV-1: week-24 interim analysis of the TMC435-C212 study. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta 2013, abstract 154LB.
25. Ingiliz P, Rockstroh JK. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012, 32:1194-1199. 10.1111/j.1478-3231.2012.02796.x, 22510096.
26. Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008, 47:36-49. 10.1097/QAI.0b013e31815ac47d, 18156990.
27. Rodriguez-Torres M, Gonzalez M, Rossi S, et al. HIV/HCV coinfected and HCV monoinfected patients have similar early HCV viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir (SOF). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012). San Francisco 2012, Abstract H1921a.